Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk

Several new therapeutic drug classes are now available to manage lipid levels. John Wilkins, MD, MS, and Donald Lloyd-Jones, MD, ScM, of the Department of Preventive Medicine and Division of Cardiology at Northwestern University Feinberg School of Medicine, discuss the use of ezetimibe, PCSK-9 inhibitors, bempedoic acid, and icosapent ethyl to manage lipid levels in patients taking statins who require additional LDL lowering.

Related Content:

• Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk
• Lipids and Lipoproteins in 2020